Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Rizzi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|December 30, 2003
Multiple active site corrections for docking and virtual screeningGuy P A Vigers, James P Rizzi
Nature|September 6, 2016
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsHyejin Cho, Xinlin Du, James P Rizzi, et al.
Journal of Medicinal Chemistry|July 9, 2019
3-[(1<i>S</i>,2<i>S</i>,3<i>R</i>)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell CarcinomaRui Xu, Keshi Wang, James P Rizzi, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral BioavailabilityErik J Hicken, Fred P Marmsater, Mark C Munson, et al.
Cancer Research|September 17, 2016
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell CarcinomaEli M Wallace, James P Rizzi, Guangzhou Han, et al.
Journal of Medicinal Chemistry|October 6, 2018
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)Paul M Wehn, James P Rizzi, Darryl D Dixon, et al.
Journal of Medicinal Chemistry|March 30, 2013
Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher speciesKevin W Hunt, Adam W Cook, Ryan J Watts, et al.
Nature|September 6, 2016
Targeting renal cell carcinoma with a HIF-2 antagonistWenfang Chen, Haley Hill, Alana Christie, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|December 30, 2003
Multiple active site corrections for docking and virtual screeningGuy P A Vigers, James P Rizzi
Nature|September 6, 2016
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsHyejin Cho, Xinlin Du, James P Rizzi, et al.
Journal of Medicinal Chemistry|July 9, 2019
3-[(1<i>S</i>,2<i>S</i>,3<i>R</i>)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell CarcinomaRui Xu, Keshi Wang, James P Rizzi, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral BioavailabilityErik J Hicken, Fred P Marmsater, Mark C Munson, et al.
Cancer Research|September 17, 2016
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell CarcinomaEli M Wallace, James P Rizzi, Guangzhou Han, et al.
Journal of Medicinal Chemistry|October 6, 2018
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)Paul M Wehn, James P Rizzi, Darryl D Dixon, et al.
Journal of Medicinal Chemistry|March 30, 2013
Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher speciesKevin W Hunt, Adam W Cook, Ryan J Watts, et al.
Nature|September 6, 2016
Targeting renal cell carcinoma with a HIF-2 antagonistWenfang Chen, Haley Hill, Alana Christie, et al.
Pageof 1